China Pharma Shares Plunge 69% on Discounted $5 Million Stock Offering

Shares of China Pharma Holdings Inc. (NYSE American: CPHI) plummeted 69% in trading on Wednesday after the company announced a registered direct offering priced at a substantial discount.

Details of the Offering

China Pharma disclosed in a statement that it had entered into an agreement to sell 2.5 million shares of its common stock at a price of $2.00 per share. The offering is expected to generate gross proceeds of approximately $5 million before deducting placement agent fees and other expenses.

The company stated that it intends to use the net proceeds for working capital and general corporate purposes. The transaction is anticipated to close on or about July 23, 2026, with FT Global Capital, Inc. acting as the exclusive placement agent.

Ad

Market Impact and Context

The sharp decline in the company's stock price reflects significant shareholder dilution resulting from the new share issuance. Offerings priced well below the current market price, as is implied by the market's reaction, can trigger a sell-off as the stock's value adjusts downward toward the new, lower offering price.

China Pharma Holdings is a specialty pharmaceutical company that develops, manufactures, and markets products in China. The company focuses on treatments for conditions with high incidence rates, such as cardiovascular and infectious diseases, and operates through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.